{"id":"bay86-6150","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, BAY86-6150 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes. The exact mechanism of action is not fully understood, but it is believed to involve the reduction of glucose reabsorption in the kidneys.","oneSentence":"BAY86-6150 is a small molecule that inhibits the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:25.599Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01625390","phase":"PHASE2, PHASE3","title":"A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06","conditions":"Hemophilia A, Hemophilia B","enrollment":10},{"nctId":"NCT01921855","phase":"PHASE1","title":"Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-01","conditions":"Hemophilia A, Hemophilia B","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BAY86-6150","genericName":"BAY86-6150","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAY86-6150 is a small molecule that inhibits the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}